Роль циклоспорина в лечении волчаночного нефрита (Обзор литературы и два наблюдения)
Аннотация
Поражение почек является одним из наиболее частых и серьезных проявлений системной красной волчанки (СКВ), преобладающим вариантом является волчаночный нефрит (ВН), который выявляется у 25-50% больных уже к моменту установки диагноза. В целом частота ВН достигает у взрослых пациентов 60-70%, а гистологические изменения обнаруживается у 90% больных
Об авторе
Е. В. Захарова
Московская городская клиническая больница имени С.П. Боткина, г. Москва
Россия
Россия
Список литературы
1. Захарова Е.В. Прогнозирование исходов системной красной волчанки и системных васкулитов с экстраренальными и почечными проявлениями. Дисс…к.м.н. М.: 2005: 94-109.
2. Тареева И.Е., Швецов М.Ю., Краснова Т.Н. и др. Артериальная гипертензия при волчаночном нефрите. Тер. Арх. 1997; 6: 13-17.
3. Тареева И.Е., Шилов Е.М., Краснова Т.Н. и др. Волчаночный нефрит в середине XX века и в начале XXI века. Тер. Арх. 2001; 6: 5-10.
4. Шилов Е.М. Иммунодепрессивная терапия активных форм нефрита. Автореф. дисс…д.м.н. М.: 1994: 34-44.
5. Шилов Е.М. Волчаночный нефрит: стратегия лечения. Тер. Арх. 2006; 5: 76-82.
6. Appel G.B., Cohen D.J., Pirani C.L. et al. Long-Term follow-up of patients with lupus nephritis. Am J Med 1987; 83: 877-885.
7. Atkins R. Lupus Erythematosus: Lupus nephritis. Нефрология и диализ 2001; 3: 84-88.
8. Austin III H.A., Kippel J.H., Balow J.E. et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Eng J Med 1986; 314: 614-619.
9. Austin III H.A., Vaughan E.M., Boumpas D.T. et al. Lupus membranous nephropathy: controlled trial of prednisone, pulse cyclophosphamide, and cyclosporine. Am J Soc Nephrol 2000; 11: 439.
10. Bansal V.K., Beto J.A. Treatment of lupus nephritis: A meta-analysis of clinical trials. Amer. J Kidney Dis 1997; 29: 193-199.
11. Boumpas D.T., Austin III H.A., Vaughan E.M. et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. The Lancet 1992; 340: 741-745.
12. Cameron J.S. Lupus Nephritis. J Am Soc Nephrol 1999; 10: 413-424.
13. Cervera R., Khamasta M.A., Font J. et al. Morbidity and mortality in systemic lupus etythematosus during a 5-year period: a multicenter prospective study of 1000 patients. European Working Party on Systemic Lupus Etythematosus. Medicine. Baltimore 1999; 78: 165-167.
14. Chun T.M., Li F.K., Tang C.S.O. Efficacy of mycofenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1165-1162.
15. Chun T.M., Li F.K., Hao W.K. et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequental immunosupression, Lupus 1999; 8: 545-551.
16. Churg J., Sobin L. Lupus nephritis. In Renal Disease. Tokio; Igakou-Schoin 1982: 127-131.
17. Contreras G., Pardo V., Leclercq B. et al. Sequential Therapies for Proliferative Lupus Nephritis. New Engl J Med 2004; 350: 971-980.
18. Conteras G., Tomzan E., Nahar N. et al. Maintenance therapies for proliferative lupus nephritis: mycophenolate mophetil, azathioprin and intravenous cycliphosphamide. Lupus 2005; 14: 890-895.
19. Donadio J.V. Treatment of membranous nephropaty in systemic lupus erythematosus. Nephrol Dial Trasplant 1992; (Suppl 1): 97-104.
20. Dostal C., Tesar V., Rychlik I. et al. Effect of 1-year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998; 7: 29-36.
21. Enriques R., Tovar J.V., Amoros F. et al. Can cyclosporin be used without steroids in systemic lupus erythematosus? Nephron 1991; 57: 367-368.
22. Favre H., Miescher A., Huang Y.P. et al. Cyclosporine in treatment of lupus nephritis. Am J Nephrol 1989; 9: 57-60.
23. Ferrario L., Bellone M., Bozzolo E. et al. Remission from lupus nephritis resistant to cyclophosphamide after additional treatment with cyclosporin A. Rheumatology 2000; 39: 218-220.
24. Feutren H., Querin S., Noel L.H. et al. Effects of cyclosporin in severe systemic lupus erythematosus. J Pediatr 1987; 111: 1063-1068.
25. Fu L.W., Yang L.Y., Chen W.P. et al. Clinical efficacy of cyclosporin: a neural in the treatment of pediatric lupus nephritis with heavy proteinuria. Br J Rheum 1998; 37: 217-221.
26. Gourley M.F., Austin III H.A., Scott D. et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Int Med 1996; 125: 549-557.
27. Hallegua D., Wallace D.J., Metzger A.L. et al. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of literature. Lupus 2000; 9: 241-251.
28. Halevy D., Radhakrishnan J. Cyclosporin in treatment of glomerular diseases. Exp Opin Invest Drugs 2000; 9: 1053-1063.
29. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus etythematosus [letter]. Arthr Rheum 1997; 40: 1725.
30. Houssiau F.A., Vasconcelos C., D’Cruz D. et al. Efficacy and safety of short course intravenous pulse cyclophosphamide regimen in proliferative lupus nephritis: interim analysis of Euro-Lupus Nephritis Trial. Lupus 2001; 10: 94.
31. Hussien M.M., Mooij J.M., Roujouleh H. Cyclosporin in treatment of lupus nephritis including two patients treated during pregnancy. Clin Nephrol 1993; 40: 160-163.
32. Illei G.G., Austin H.A., Crane M. et al. Combination therapy with pulse cyclophosphamide plus pulse methyl-prednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 296-98.
33. Kolasinski S.L., Chung J.B., Albert D.A. What do we know about lupus membranous nephropathy? An analytic review. Arthr Rheum 2002; 47: 450-455.
34. Leehey D.J., Katz A.I., Azaran A.H. et al. Silent diffuse lupus nephritis: long-term follow-up. Am J Kidney Dis 1983; 2: 188-196.
35. Lefrancois N., Deteix P., Laville M. et al. Treatment of systemic lupus with cyclosporin A: a patient with a one-year follow-up. Kidney Int 1984; 26: 160-163.
36. Miescher P.A., Miescher A. Combined cyclosporin-streoid treatment of systemic lupus erythematous. In: Cyclosporin in autoimmune disease. R. Schindler (Ed), Springer-Verlag, Berlin 1985: 334.
37. Miescher P.A., Favre H., Mihatsch M.J. et al. The place of cyclosporin A in the treatment of connective tissue diseases. Transplant Proc 1994; suppl 4: 224-237.
38. Mok C.C., Ying K.Y., Lau C.S. et al. Treatment of Pure Membranous Lupus Nephropathy With Prednisone and Azathioprine: An Open-Lable trial. An J Kidney Dis 2004; 43: 269-276.
39. Moroni G., Maccario M., Banfi G. et al. Treatment of membranous lupus nephritis. Am J Kidney Dis 1998; 31: 681-686.
40. Nossent H.C., Koldingsnes W. Long-term efficacy of azathioprine treatment for proliferative lupus nephitis. Rheumatology 2000; 39: 969-974.
41. Ponticelli C. Current treatment recommendation for lupus nephritis. Drugs 1990; 40: 537-550.
42. Ponticelli C. Treatment of proliferative lupus nephritis. Acta Nephrologica 2005; 19 (2): 47-52.
43. Radhakrishnan J., Szabolcs M., D’Agati V. et al. Lupus membranous nephropathy (LMN): Course and prognosis in 50 patients. Am J Soc Nephrol 1993: 284 (Abstract).
44. Radhakrishnan J., Kunis C.L., D’Agati V. et al. Cyclosporine treatment of lupus membranous nephropathy. Clin Nephrol 1994; 42: 147-154.
45. Steinberg A.D., Muir J., Scott D.E. et al. Approach to lupus nephritis based upon randomized trials. Contrib Nephrol 1992; 99: 46-54.
46. Tam L.S., Li E.K., Szeto C.C. et al. Treatment of membranous lupus nephritis with prednisone, azathioprine and cyclosporine A. Lupus 2001; 10: 827-829.
47. Tam L.S., Li E.K., Leung C.V. et al. Long term treatment of lupus nephritis with cyclosporin A. QJM 1998; 91: 573-580.
48. Tokuda M., Kurata N., Mizoguchi A. et al. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthr Rheum 1994; 37: 551-558.
49. Uramoto K.M., Michet C.J., Thumboo J. et al. Trends in the incidence and mortality of systemic lupus etythematosus 1950-1992. Arthr Rheum 1999; 42: 46-50.
50. Urowitz M.B., Gladman D.D., Abu-Shakra M. et al. Evolving spectrum of mortality and morbidity in SLE. Lupus 1999; 8: 253-255.
51. Valery A., Radhakrishnan J, Estes D. et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994; 42: 71-78.
52. Weening J.J., D’Agati V.M., Schwartz M.M. et al. The classification of glomerulonephtitis in systemic lupus etythematosus revisited. J Am Soc Nephrol 2004; 15: 241-251.
53. Weening J.J., D’Agati V.M., Schwartz M.M. et al. The classification of glomerulonephtitis in systemic lupus etythematosus revisited. Kidney Int 2004; 65: 521-530.
Рецензия
Для цитирования:
Захарова Е.В. Роль циклоспорина в лечении волчаночного нефрита (Обзор литературы и два наблюдения). Нефрология и диализ. 2007;9(2):192-197.
For citation:
Zakharova E.V. Role of cyclosporin in treatment of lupus nephritis (Review and case report). Nephrology and Dialysis. 2007;9(2):192-197. (In Russ.)
Просмотров:
5
Послать статью по эл. почте 